Technical Analysis for SHPG - Shire plc
|Grade||Last Price||% Change||Price Change|
SHPG closed down 1.74 percent on Friday, October 20, 2017, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Oct 27
|Weak or Absent||Down||Down||Down|
|See historical SHPG trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 20||Lower Bollinger Band Walk||Other||0.00%|
|Oct 19||Stochastic Reached Oversold||Other||-1.74%|
|Oct 19||Bollinger Band Squeeze||Range Contraction||-1.74%|
|Oct 19||Lower Bollinger Band Walk||Other||-1.74%|
|Oct 19||Calm After Storm||Range Contraction||-1.74%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SHPG news...
|52 Week High||192.64|
|52 Week Low||139.36|
|200-Day Moving Average||167.2604|
|50-Day Moving Average||151.5256|
|20-Day Moving Average||151.815|
|10-Day Moving Average||150.678|
|Average True Range||2.9272|
|Chandelier Exit (Long, 3 ATRs )||149.0684|
|Chandelier Exit (Short, 3 ATRs )||153.8116|
|Upper Bollinger Band||157.3716|
|Lower Bollinger Band||146.2584|
|Percent B (%b)||-0.09|
|MACD Signal Line||-0.8115|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||148.15|
|Resistance 3 (R3)||148.39||147.68||147.66|
|Resistance 2 (R2)||147.68||146.94||147.55||147.50|
|Resistance 1 (R1)||146.46||146.48||146.11||146.22||147.34|
|Support 1 (S1)||144.53||145.01||144.18||144.29||143.16|
|Support 2 (S2)||143.82||144.55||143.69||143.00|
|Support 3 (S3)||142.60||143.82||142.84|
|Support 4 (S4)||142.36|